Real-World Evidence With Five-Year Data (2017-2022) on the use of Cladribine Tablets in Patients With Multiple Sclerosis in England: An Updated Analysis From the CLARENCE Study

被引：0
|
作者：
Brownlee, Wallace [1 ]
Amin, Amerah [2 ]
Ashton, Luke [2 ]
Herbert, Alex [2 ]
机构：
[1] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[2] Merck Serono Ltd, Merck KGaA, Feltham, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1558/603
引用
收藏
页码：993 / 994
页数：2
相关论文
共 50 条
  • [1] Real-world use of cladribine tablets (Completion rates and treatment persistence) In patients with multiple sclerosis in England: the CLARENCE Study
    Brownlee, W.
    Amin, A.
    Ashton, L.
    Herbert, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 666 - 667
  • [2] Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study
    Brownlee, Wallace
    Amin, Amerah
    Ashton, Luke
    Herbert, Alex
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [3] A Multicenter Real-World Data of Cladribine Tablets in Patients with Multiple Sclerosis in Turkey
    Koseoglu, Mesrure
    Omerhoca, Sami
    Balci, Fatma Belgin
    Unal, Aysun
    Ozdemir, Zeynep
    Yuksel, Burcu
    Celik, Rabia Gokcen Gozubatik
    Toprak, Ufuk Emre
    Gursoy, Esra Azize
    Icen, Nilufer Kale
    Altunrende, Burcu
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1017 - 1017
  • [4] 5 YEARS OF REAL-WORLD DATA ON THE USE OF CLADRIBINE TABLETS FOR THE TREATMENTS OF MULTIPLE SCLEROSIS IN PORTUGAL
    Ribeiro, M.
    Pinto, D.
    VALUE IN HEALTH, 2023, 26 (12) : S16 - S16
  • [5] Real-World Effectiveness of Cladribine Tablets in Individuals with Multiple Sclerosis: Data from a Multi-Center Italian Study
    Lucchini, Matteo
    Borriello, Giovanna
    Haggiag, Shalom
    Nicoletti, Carolina
    Fantozzi, Roberta
    Buscarinu, Maria Chiara
    Ferrazzano, Gina
    Cortese, Antonio
    Marinelli, Fabiana
    Monteleone, Fabrizia
    Centonze, Diego
    Conte, Antonella
    Ferraro, Elisabetta
    Gasperini, Claudio
    Marfia, Girolama Alessandra
    Pozzilli, Carlo
    Salvetti, Marco
    Barbuti, Elena
    Bianco, Assunta
    Carlomagno, Vincenzo
    Cruciani, Alessandro
    De Giglio, Laura
    Dionisi, Claudia
    Ianniello, Antonio
    Malimpensa, Leonardo
    Nasello, Martina
    Nociti, Viviana
    Prosperini, Luca
    Tortorella, Carla
    Mirabella, Massimiliano
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 376 - 377
  • [6] Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4-Results from a German cladribine cohort
    Kowarik, Markus C.
    Ernst, Michael
    Woitschach, Lara
    Cepek, Lukas
    Rau, Daniela
    Kuehnler, Benedicta
    Schlemilch-Paschen, Sylke
    Grothe, Christoph
    Schwab, Matthias
    Joestingmeyer, Petra
    Kleinschnitz, Christoph
    Pul, Refik
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 88
  • [7] The effect of alemtuzumab treatment in relapsing remitting multiple sclerosis: real-world data from a five-year prospective one center study
    Sandgren, S.
    Novakova, L.
    Axelsson, M.
    Malmestrom, C.
    Zetterberg, H.
    Lycke, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 615 - 615
  • [8] Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
    Oreja-Guevara, Celia
    Brownlee, Wallace
    Celius, Elisabeth G.
    Centonze, Diego
    Giovannoni, Gavin
    Hodgkinson, Suzanne
    Kleinschnitz, Christoph
    Kubala Havrdova, Eva
    Magyari, Melinda
    Selchen, Daniel
    Vermersch, Patrick
    Wiendl, Heinz
    Van Wijmeersch, Bart
    Salloukh, Hashem
    Yamout, Bassem
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 69
  • [9] A five-year observational prospective mono centre study of efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
    Sandgren, Sofia
    Novakova, Lenka
    Nordin, Anna
    Axelsson, Markus
    Malmestrom, Clas
    Zetterberg, Henrik
    Lycke, Jan
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 632 - 633
  • [10] The effect of alemtuzumab treatment on neurodegeneration in relapsing remitting multiple sclerosis: real-world data from a five-year prospective one center study
    Sandgren, S.
    Novakova, L.
    Axelsson, M.
    Malmestrom, C.
    Zetterberg, H.
    Lycke, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 248 - 249
12345